New Frontiers in Feline Chronic Kidney Disease

September 17, 2026

by Theresa Gleason EdD MS and Noelle Giddings DVM

 

Chronic Kidney Disease (CKD) remains the most prevalent metabolic disorder in domestic cats, impacting an estimated 30–50% of the geriatric feline population.5 Cats are evolutionary experts at masking discomfort, which often results in a “silent” progression where clinical symptoms only emerge after significant renal function is lost. However, the landscape of feline medicine in 2026 has shifted from reactive care to proactive, biology-driven intervention in the course of individual cases of CKD.

The Gut-Kidney Axis and Porus One

Modern treatment now focuses on the “gut-kidney axis” to reduce the toxic load on the renal system. When kidneys fail, they struggle to filter uremic toxins, many of which are byproducts of protein digestion in the gut.

Research by Summers and Quimby (2024) has highlighted the efficacy of Renaltec, the active ingredient in Porus One.6 These are microscopic carbon spheres administered orally that travel through the intestines. They physically bind to toxin precursors, such as indole, before they can enter the bloodstream.6

Advanced Diagnostics: SDMA and FGF-23

Early detection is the cornerstone of 2026 renal management. The International Renal Interest Society (IRIS) updated its staging protocols to prioritize sensitive biomarkers over traditional creatinine.3 Two of these biomarkers are:

  • SDMA (Symmetric Dimethylarginine): Unlike creatinine, SDMA is not influenced by a cat’s muscle mass. It can detect kidney function loss as early as the loss of 25–40% function, whereas creatinine often remains within normal limits until 75% of function is already gone.2 and 3
  • FGF-23 (Fibroblast Growth Factor 23): Acting as the “Phosphorus Police,” this hormone rises significantly before phosphorus levels appear elevated on standard blood panels.1 Establishing a reference interval for FGF-23 is now considered a primary trigger to initiate phosphorus-restricted renal diets.4

IRIS Staging Summary (2023-2026)

Stage Creatinine (mg/dL) SDMA (μg/dL) Clinical Significance
Stage 1 < 1.6 < 18 Early damage; no clinical signs.
Stage 2 1.6 – 2.8 18 – 25 Mild azotemia; kidneys struggling to concentrate urine.
Stage 3 2.9 – 5.0 26 – 38 Moderate azotemia; weight loss and increased thirst.
Stage 4 > 5.0 > 38 Severe crisis; high risk of uremic poisoning.

 

The Future of Feline Longevity

The outlook for cats diagnosed with CKD in 2026 is defined by “management through precision.” By integrating early nutritional intervention (Stage 1 renal diets) with gut-toxin adsorbents, veterinarians are successfully extending the life expectancy of feline CKD patients by years rather than months.

Editor’s note: also see Cat Talk’s previous article on Porous One here.

References:

  • Geddes, R.F, N.C Finch, J Elliott, and H.M Syme. 2013. “Fibroblast Growth Factor 23 in Feline Chronic Kidney Disease.” Journal of Veterinary Internal Medicine(United States) 27 (2): 234–41. https://doi.org/10.1111/jvim.12044
  • Hall, J.A, M Yerramilli, E Obare, and D.E Jewell. 2014. “Comparison of Serum Concentrations of Symmetric Dimethylarginine and Creatinine as Kidney Function Biomarkers in Cats with Chronic Kidney Disease.” Journal of Veterinary Internal Medicine(United States) 28 (6): 1676–83. https://doi.org/10.1111/jvim.12445
  • International Renal Interest Society (IRIS). 2023. “Guidelines – Staging of CKD.” IRIS. https://www.iris-kidney.com/iris-guidelines-1
  • Lapsina, Sandra, Jennifer von Luckner, Nicole Nagler, Simon Franz Müller, Elisabeth Müller, and Ingo Schäfer. 2024. “Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats.” Animals (Basel)(Switzerland) 14 (11): 1670. https://doi.org/10.3390/ani14111670
  • Grecu, Mariana, Robert Capotă, Cristina Horhogea, Cristina Rîmbu, Valentin Năstasă, and Oana Tănase. 2025. “Epidemiology of Chronic Kidney Disease (CKD) in Cats: An Analysis of the Factors Involved.” Life (Basel, Switzerland)(Switzerland) 15 (12): 1856. https://doi.org/10.3390/life15121856
  • Summers, Stacie, and Jessica Quimby. 2024. “Insights into the Gut-Kidney Axis and Implications for Chronic Kidney Disease Management in Cats and Dogs.” The Veterinary Journal (1997)(England) 306 (August): 106181. https://doi.org/10.1016/j.tvjl.2024.106181

 

Noelle Giddings is a small animal veterinarian. She breeds and shows solid and bicolor Persians and Exotics under the cattery name Purrcasso. She acts as a veterinary consultant for the other writers.

Dr. Theresa Gleason holds a doctorate and a master’s of science, emphasizing nursing and education. She is passionate about Siberians and is dedicated to sharing her knowledge through writing and working as a copy editor for Cat Talk.